ArticleThe journal of gene medicine2026
Identification and Experimental Validation of PANoptosis Key Genes for Constructing a PANoptosis Risk Diagnostic Model in Intervertebral Disc Degeneration.
Article in The journal of gene medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIntervertebral disc degeneration (IDD) represents a significant health concern globally. This study aimed to identify the PANoptosis key genes (PKGs) associated with IDD and construct a risk diagnosis model
methodsSingle-cell sequencing, machine learning algorithms, and LASSO regression were employed to identify PKGs and develop a risk model. The expression of identified PKGs was validated in human IDD clinical tissues using qRT-PCR, Western blot, and immunohistochemistry. The therapeutic effect of ACSBG1 knockdown was further evaluated in a rat IDD model by histological analysis.
resultsThe seven most representative PKGs of IDD (ACSBG1, FXYD1, APCS, CEACAM1, ERAP2, ABL1, and FZD3) were identified. Utilizing these seven PKGs, an IDD PANoptosis risk diagnosis model was constructed and validated. Immune infiltration analysis revealed a significant association between the PANoptosis risk of IDD and immune cells, particularly neutrophils. Clinical validation confirmed that ACSBG1, FXYD1, APCS, and CEACAM1 were upregulated, while ERAP2, ABL1, and FZD3 were downregulated in nucleus pulposus tissues of IDD patients. In a rat model, ACSBG1 knockdown markedly attenuated disc degeneration, preserving disc structure and increasing proteoglycan content.
conclusionThis study established an IDD PANoptosis risk diagnosis model and demonstrated that targeting ACSBG1 exerted therapeutic effects in vivo, providing new insights into the diagnosis and treatment of IDD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.